Compounded vs brand GLP-1 medicines: what FDA has said as of October 2026

FDA's page on unapproved GLP-1 drugs was retrieved on 9 October 2026 and is marked current as of 1 October 2026. As of that retrieval, FDA says that compounded GLP-1 drugs are not FDA approved, so the agency does not review them for safety, effectiveness or quality before they are marketed ^[1]. FDA states that compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug. It adds that a compounded drug might be appropriate when the approved drug is not commercially available ^[1]. FDA treats a company's claim that its compounded product matches an approved drug as a warning sign for consumers ^[1].

Terms used in this guide

FDA uses "GLP-1 drugs" for glucagon-like peptide-1 receptor agonists, a group in which it includes semaglutide and tirzepatide ^[1]. An active pharmaceutical ingredient (API), which FDA also calls a bulk drug substance, is the raw drug material that compounders use to make a finished product ^[1]. A titration schedule is the pace at which a dose is increased over time ^[1]. FDA describes counterfeit drugs as illegal products that claim to be authentic but could contain the wrong ingredients, too little, too much or no active ingredient, or other harmful ingredients ^[1]. Body mass index (BMI) is a measure of weight in relation to height, and NIDDK defines obesity as a BMI of 30 or greater ^[2].

The FDA-approved options

NIDDK, part of the National Institutes of Health, lists six drugs that FDA has approved for long-term weight management. Three of them are liraglutide (Saxenda), semaglutide (Wegovy) and tirzepatide (Zepbound) ^[2]. According to NIDDK, a health care professional may prescribe a weight management medication to an adult with a BMI of 30 or greater. The same applies to a BMI of 27 or greater with weight-related problems such as high blood pressure or type 2 diabetes ^[2]. NIDDK also states that FDA has approved semaglutide (Wegovy) for children ages 12 and older ^[2].

NIDDK reports that, on average after 1 year, adults taking prescription weight medications within a lifestyle program lose 3% to 12% more of their starting body weight than people in a lifestyle program without medication ^[2]. This is a consumer-reference summary across several medications, not a trial result for any single product, and is background only ^[2]. NIDDK also states that if a person does not lose at least 5% of starting weight after 12 weeks on the full dose, the health care professional will probably advise stopping the medication ^[2]. NIDDK's figures refer to FDA-approved medications, and FDA states that it does not review compounded drugs for effectiveness before they are marketed ^[1][2].

FDA's specific concerns with compounded GLP-1 drugs

Multiple-dose vials are the first concern. FDA notes that compounded GLP-1 medications may be dispensed in vials holding multiple doses for self-injection. It generally recommends that such vials of sterile medication be used within 28 days after first use, because contamination risk rises after that point ^[1]. FDA recommends that consumers discard the vial within 28 days of first use even if medication remains, and even if the compounder's instructions allow longer use. It also recommends a new, sterile needle and syringe for every dose ^[1].

Shipping and storage are the second concern. FDA states that injectable GLP-1 drugs require refrigeration as indicated in their package inserts, and it has received complaints of compounded products arriving warm or with inadequate ice packs ^[1]. The agency recommends that patients not use any injectable GLP-1 drug that arrives warm or without sufficient refrigeration, because this can affect quality ^[1].

Dosing errors are the third. FDA has received multiple adverse event reports, some involving hospitalization, that may be related to dosing errors with compounded injectable semaglutide. These errors include patients measuring incorrect doses and, in some cases, health care professionals miscalculating doses ^[1]. FDA has also received reports that may be related to compounded semaglutide or tirzepatide prescribed beyond the doses in the approved label, meaning larger single doses, more frequent doses or faster titration ^[1]. Reported symptoms included nausea, vomiting, diarrhea, abdominal pain and constipation, and FDA asks prescribers to be vigilant when setting doses and titration schedules for compounded products ^[1].

Ingredient identity is the fourth. FDA states that some compounded semaglutide may be made from salt forms, including semaglutide sodium and semaglutide acetate, which are different active ingredients from those in the approved drugs ^[1]. The agency says it lacks information on whether these salts share the approved ingredient's chemical and pharmacologic properties, and that it is not aware of any lawful basis for their use in compounding ^[1]. Separately, FDA states that retatrutide and cagrilintide cannot be used in compounding under federal law, are not components of FDA-approved drugs, and have not been found safe and effective for any condition ^[1].

Label fraud is the fifth. FDA is aware of fraudulent compounded semaglutide and tirzepatide with false label information. Some labels name pharmacies that do not exist, and others name a licensed pharmacy that, according to FDA, did not make the product ^[1].

FDA has also set up a green list import alert, 66-80, to keep GLP-1 APIs with potential quality concerns out of the U.S. supply chain, with an exemption for manufacturers that appear compliant with FDA manufacturing standards ^[1]. FDA states that this alert does not create new limits on the legal compounding of GLP-1 drugs ^[1].

What the adverse event counts can and cannot show

As of May 31, 2026, FDA had received 990 adverse event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide ^[1]. These are spontaneous reports, not a controlled study, and FDA notes that it is not always possible to determine whether an event resulted from the drug or from other factors ^[1]. FDA also states that federal law does not require state-licensed pharmacies that are not outsourcing facilities to report adverse events, so it considers events from compounded versions likely underreported ^[1]. FDA observes that many reported events appear consistent with those seen with the approved versions ^[1]. Because the reports are uncontrolled and likely incomplete, they do not provide a rate of harm or a comparison between compounded and approved products ^[1].

Products outside the licensed pharmacy system

FDA is aware of counterfeit Ozempic marketed in the U.S. and has issued warning letters over illegally marketed semaglutide and tirzepatide sold online ^[1]. It has also warned companies selling semaglutide, tirzepatide, retatrutide, survodutide or mazdutide labeled "for research purposes" or "not for human consumption" while supplying dosing instructions to consumers ^[1]. FDA describes these products as of unknown quality and urges consumers not to buy them ^[1].

Telehealth warning signs FDA lists

• The company claims its compounded product matches an approved drug ^[1].
• Prices are deeply discounted or seem too good to be true ^[1].
• The medicine looks different from what was previously dispensed or pictured, or arrives with broken packaging or no instructions for use ^[1].
• No screening and prescription by a licensed doctor is required before the medicine is provided ^[1].
• No licensed doctor is available for questions after the medicine arrives ^[1].
• The label has spelling errors or incorrect pharmacy addresses, or names a pharmacy that may be fraudulent ^[1].

Where AthleticsMD fits

AthleticsMD offers ShredRx, a physician-guided medical weight loss program, at its Columbia and Laurel/Fort Meade, Maryland locations ^{[AthleticsMD]}. The FDA questions below apply to any program a reader is weighing, including this one ^{[1][AthleticsMD]}.

How to decide

• Is there an FDA-approved drug that meets the medical need, and is it commercially available? FDA ties appropriate compounding to cases where it does not or is not ^[1].
• Does the product name semaglutide or tirzepatide itself, rather than a salt form such as semaglutide sodium or semaglutide acetate ^[1]?
• Does the product contain retatrutide or cagrilintide, which FDA states cannot be used in compounding ^[1]?
• Is the dispensing pharmacy state-licensed, and do its name and address on the label match a real pharmacy ^[1]?
• Did a licensed clinician screen and prescribe, and is one available afterward ^[1]?
• Do the prescribed doses and titration schedule stay within the approved label, and has someone shown the patient how to measure each dose ^[1]?
• If the product comes in a multiple-dose vial, will it be used up or discarded within 28 days of first use ^[1]?
• Did the shipment arrive cold, with adequate ice packs, intact packaging and instructions ^[1]?
• Is there a plan to review progress at 12 weeks on the full dose, as NIDDK describes ^[2]?
• Has the clinician discussed cost and insurance coverage, which NIDDK lists as factors in choosing a medication ^[2]?

Adverse events or quality problems with any of these medicines can be reported to FDA's MedWatch program ^[1].

Limitations

This guide rests on two government sources: an FDA safety page and an NIDDK consumer reference ^[1][2]. Neither provides head-to-head clinical data on compounded versus approved GLP-1 products, and FDA's adverse event figures come from reports that are likely incomplete and cannot establish causation ^[1][2]. The FDA page may change after its retrieval on 9 October 2026 ^[1].